Business Context and Reporting Period
This Form 8-K, dated May 19, 2020, is filed by Bristol-Myers Squibb Company (BMY) to disclose unaudited pro forma condensed combined financial information. The filing relates to the completed acquisition of Celgene Corporation (closed November 20, 2019) and the subsequent disposition of Celgene's OTEZLA (apremilast) product line. The pro forma data presented reflects the combined entity for the year ended December 31, 2019.
Key Financial Metrics and Debt Structure
The filing details significant debt issuances undertaken to fund the Celgene Merger. Specific revenue, profit, or cash flow figures for the pro forma period are not contained within the text of this report but are referenced as being included in Exhibit 99.1.
- May 2019 Notes: Approximately $19 billion in senior unsecured notes issued to partially fund the Merger.
- November 2019 Notes: Approximately $18.5 billion in senior unsecured notes issued following the settlement of exchange offers for Celgene's outstanding notes.
- Total Notes Issued: Approximately $37.5 billion in aggregate principal amount (May Notes and November Notes combined).
- Exchange Offers: Bristol-Myers Squibb offered to exchange up to approximately $19.9 billion of Celgene's outstanding notes for new notes and cash.
Material Changes and Transactions
The primary material change reported is the execution of Registered Exchange Offers. Bristol-Myers Squibb intends to exchange the previously issued private Notes (May and November Notes) for new "Registered Notes" with identical principal amounts, interest rates, maturities, and denominations. The key distinction is that the Registered Notes will not contain the transfer restrictions applicable to the original Notes.
Guidance, Outlook, and Risks
The filing explicitly states that the pro forma financial information is for informational purposes only. It does not represent actual results of operations that would have been achieved had the companies been combined during the presented periods, nor is it intended to project future results. No specific forward-looking guidance or management commentary regarding future earnings is provided in this text.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific unaudited pro forma condensed combined statement of earnings for the year ended December 31, 2019.
- Verify the terms of the Registered Exchange Offers to confirm the removal of transfer restrictions on the $37.5 billion in debt.
- Assess the impact of the OTEZLA product line disposition on the pro forma revenue and earnings figures.
- Confirm the final settlement details of the exchange offers for Celgene's outstanding notes.